Biotech Firm Lycia Therapeutics Makes US Market Debut, Shares Surge Over 32%

Stock News

Yesterday

On Friday, biotech company Lycia Therapeutics (LYCA.US), which focuses on treatments for allergies and autoimmune diseases, made its debut on the US stock market. Its shares surged more than 32% after the opening bell, reaching $23.90. The IPO price was set at $18.

Lycia Therapeutics is dedicated to developing therapies designed to degrade disease-causing extracellular proteins, with an initial focus on autoimmune, inflammatory, and allergic diseases. Its technology platform, called LYTAC (lysosome-targeting chimera), is based on research conducted at Stanford University by Nobel laureate Carolyn Bertozzi.

Its lead drug candidate, LCA-0061, is designed to degrade immunoglobulin E (IgE) for the treatment of allergic diseases including food allergies, and is currently in Phase 1 clinical trials.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1161901255"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161901255\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161901255?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-24 00:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161901255","market":"fut","top_or_hot":-1,"title":"Biotech Firm Lycia Therapeutics Makes US Market Debut, Shares Surge Over 32%","media":"Stock News","content":"<p>On Friday, biotech company <b>Lycia Therapeutics (LYCA.US)</b>, which focuses on treatments for allergies and autoimmune diseases, made its debut on the US stock market. Its shares surged more than 32% after the opening bell, reaching $23.90. The IPO price was set at $18.<br><br><b>Lycia Therapeutics</b> is dedicated to developing therapies designed to degrade disease-causing extracellular proteins, with an initial focus on autoimmune, inflammatory, and allergic diseases. Its technology platform, called LYTAC (lysosome-targeting chimera), is based on research conducted at Stanford University by Nobel laureate Carolyn Bertozzi.<br><br>Its lead drug candidate, LCA-0061, is designed to degrade immunoglobulin E (IgE) for the treatment of allergic diseases including food allergies, and is currently in Phase 1 clinical trials.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Firm Lycia Therapeutics Makes US Market Debut, Shares Surge Over 32%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Firm Lycia Therapeutics Makes US Market Debut, Shares Surge Over 32%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-24 00:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On Friday, biotech company <b>Lycia Therapeutics (LYCA.US)</b>, which focuses on treatments for allergies and autoimmune diseases, made its debut on the US stock market. Its shares surged more than 32% after the opening bell, reaching $23.90. The IPO price was set at $18.<br><br><b>Lycia Therapeutics</b> is dedicated to developing therapies designed to degrade disease-causing extracellular proteins, with an initial focus on autoimmune, inflammatory, and allergic diseases. Its technology platform, called LYTAC (lysosome-targeting chimera), is based on research conducted at Stanford University by Nobel laureate Carolyn Bertozzi.<br><br>Its lead drug candidate, LCA-0061, is designed to degrade immunoglobulin E (IgE) for the treatment of allergic diseases including food allergies, and is currently in Phase 1 clinical trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1161901255","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161901255","pubTimestamp":1792773372,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On Friday, biotech company Lycia Therapeutics (LYCA.US), which focuses on treatments for allergies and autoimmune diseases, made its debut on the US stock market. Its shares surged more than 32%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159837":"生物科技","BK4585":"ETF&股票定投概念","AGNG":"Global X Aging Population ETF","LENZ":"Therapeutics","IEIH":"iShares Evolved U.S. Innovative Healthcare ETF","LNGR":"Global X Longevity Thematic ETF","BK4139":"生物科技","BK4581":"高盛持仓","XBI":"SPDR S&P Biotech ETF","BK4588":"碎股","GDOC":"Goldman Sachs Future Health Care Equity ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","MEDX":"HORIZON KINETICS MEDICAL ETF","LYCA":"Lycia Therapeutics","BK4007":"制药","SYNB":"PUTNAM BIOREVOLUTION ETF","BK4539":"次新股"},"translate_title":"生物技术公司 Lycia Therapeutics 在美国市场首次亮相，股价飙升超过 32%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159837":1,"LENZ":1,"LNGR":1,"LYCA":1,"HBImain":1,"GDOC":1,"SYNB":1,"XBI":1,"IEIH":1,"AGNG":1,"IBBJ":1,"MEDX":1},"content_text":"On Friday, biotech company Lycia Therapeutics (LYCA.US), which focuses on treatments for allergies and autoimmune diseases, made its debut on the US stock market. Its shares surged more than 32% after the opening bell, reaching $23.90. The IPO price was set at $18.Lycia Therapeutics is dedicated to developing therapies designed to degrade disease-causing extracellular proteins, with an initial focus on autoimmune, inflammatory, and allergic diseases. Its technology platform, called LYTAC (lysosome-targeting chimera), is based on research conducted at Stanford University by Nobel laureate Carolyn Bertozzi.Its lead drug candidate, LCA-0061, is designed to degrade immunoglobulin E (IgE) for the treatment of allergic diseases including food allergies, and is currently in Phase 1 clinical trials.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}